Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Healthy females~* 17(in states where the legal age of consent to receive contraceptives is 17)-40 years~* Regular, consistent menstrual cycles between 25 and 35 days~* Sexually active women requesting birth control~* In good general health, confirmed by medical history, physical (including gynecologic) examination and screening laboratory values~Exclusion Criteria:~* Known or suspected pregnancy;~* Lactating women~* Significant skin reaction to transdermal preparations or sensitivity to surgical / medical tape~* Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic)~* Use of other contraceptive methods than study medication

- Gender: FEMALE
- Minimum Age: 17 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- AG200-15 (cycles 1-13) (Type: EXPERIMENTAL): AG200-15 containing ethinyl estradiol and levonorgestrel. Type of intervention is drug.
- Lessina crossover to AG200-15 (Type: ACTIVE_COMPARATOR): Lessina containing ethinyl estradiol and levonorgestrel for 6 cycles followed by AG200-15 for 6 cycles. Type of intervention is drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).